8 years of historical data (2018–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mirum Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 87.3x P/FCF, 38% below the 5-year average of 141.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.8B | $4.0B | $2.0B | $1.2B | $663M | $484M | $441M | $564M | — |
| Enterprise Value | $4.8B | $4.0B | $2.1B | $1.2B | $637M | $455M | $302M | $555M | — |
| P/E Ratio → | -196.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.19 | 7.61 | 5.83 | 6.48 | 8.60 | 25.27 | — | — | — |
| P/B Ratio | 14.72 | 12.60 | 8.71 | 4.85 | 4.67 | 4.02 | 2.56 | 4.32 | — |
| P/FCF | 87.28 | 72.26 | 210.57 | — | — | — | — | — | — |
| P/OCF | 85.79 | 71.03 | 190.32 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.65 | 6.12 | 6.59 | 8.26 | 23.77 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 72.64 | 220.78 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Mirum Pharmaceuticals, Inc. earns an operating margin of -4.2%. Operating margins have expanded from -58.6% to -4.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -8.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.8% | 80.8% | 75.8% | 74.8% | 83.9% | 90.1% | — | — | — |
| Operating Margin | -4.2% | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | — | — | — |
| Net Profit Margin | -4.5% | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.6% | -8.6% | -37.1% | -83.7% | -103.5% | -57.5% | -68.3% | -87.6% | — |
| ROA | -3.1% | -3.1% | -13.4% | -32.7% | -41.9% | -31.4% | -53.3% | -52.9% | -33.4% |
| ROIC | -5.1% | -5.1% | -22.2% | -42.3% | -94.8% | -208.5% | -100.7% | -137.5% | — |
| ROCE | -3.7% | -3.7% | -15.9% | -25.8% | -48.6% | -73.1% | -58.6% | -59.8% | -5.9% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $21M ($317M total debt minus $297M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.01 | 1.01 | 1.41 | 1.24 | 0.02 | 0.02 | 0.02 | 0.03 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.07 | 0.42 | 0.09 | -0.18 | -0.24 | -0.81 | -0.06 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -35.64 |
| Debt / FCF | — | 0.38 | 10.21 | — | — | — | — | — | — |
| Interest Coverage | — | — | -6.12 | -7.23 | -8.21 | -9.86 | -311.33 | — | — |
Short-term solvency ratios and asset-utilisation metrics
Mirum Pharmaceuticals, Inc.'s current ratio of 2.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.45x to 2.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | 2.67 | 3.10 | 4.45 | 2.94 | 3.91 | 12.80 | 9.13 | 21.22 |
| Quick Ratio | 2.55 | 2.55 | 2.93 | 4.19 | 2.85 | 3.88 | 12.80 | 9.13 | 21.22 |
| Cash Ratio | 1.86 | 1.86 | 2.22 | 3.29 | 2.34 | 3.68 | 12.56 | 8.92 | 21.22 |
| Asset Turnover | — | 0.62 | 0.50 | 0.29 | 0.22 | 0.06 | — | — | — |
| Inventory Turnover | 4.03 | 4.03 | 3.64 | 2.11 | 2.22 | 1.26 | — | — | — |
| Days Sales Outstanding | — | 86.35 | 84.82 | 133.11 | 113.65 | 62.31 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mirum Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.1% | 1.4% | 0.5% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $50M | $48M | $41M | $34M | $30M | $25M | $23M | $23M |
Compare MIRM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| MIRMYou | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MIRM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonMirum Pharmaceuticals, Inc.'s current P/E ratio is -196.4x. This places it at the 50th percentile of its historical range.
Mirum Pharmaceuticals, Inc.'s return on equity (ROE) is -8.6%. The historical average is -63.7%.
Based on historical data, Mirum Pharmaceuticals, Inc. is trading at a P/E of -196.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Mirum Pharmaceuticals, Inc. has 80.8% gross margin and -4.2% operating margin.